KPV

What is KPV?

α-melanocyte-stimulating hormone (α-MSH) is a 13-amino-acid hormone derived from proopiomelanocortin; it stimulates melanin production in the skin and also has inflammation-suppressing effects in the body. According to a 2008 review, the main obstacle limiting the use of α-MSH in inflammatory diseases is that it darkens skin color. KPV, made of the last three amino acids of the hormone, has been put forward as an alternative candidate because it retains the anti-inflammatory effect but does not carry the pigment effect. ^[2] Tanning peptides that mimic the pigment effect of α-MSH are in a separate guide: Melanotan.

How KPV acts is not clear. In a mouse study, the effect of KPV in reducing inflammatory cell migration was not abolished by a substance blocking MC3/MC4 melanocortin receptors and persisted in mice with a non-functional MC1 receptor; the authors proposed that KPV acts not through melanocortin receptors but most likely by suppressing the function of the inflammatory messenger IL-1β. ^[3] Studies with intestinal cells, on the other hand, reported that KPV enters cells through a peptide transporter called PepT1, which is found in the small intestine and increases in the inflamed colon. ^[4] According to the FDA’s 2026 assessment, the molecular targets underlying the pharmacological effects of KPV are still unknown. ^[1]

What was found in animal colitis models?

KPV’s recognition as a “gut peptide” rests on mouse models that mimic inflammatory bowel disease. In these models, colitis is induced with chemicals that damage the intestine (DSS, TNBS) or by transferring immune cells.

The common limits of these studies are clear. All are mouse models, and chemically induced or transfer-induced colitis mimics only some aspects of Crohn’s disease or ulcerative colitis in humans. Two studies used nanoparticle and gel systems specially designed to deliver KPV to the colon; the authors of the Laroui study present this system as a way of overcoming physiological barriers by targeting the drug to the inflamed region. ^{[6] [7]} The results cannot be transferred to products that do not contain these systems or to humans. Mouse doses are not converted to humans in this guide.

Animal studies outside colitis paint a similar picture: in mice, KPV reduced accumulation of inflammatory cells in peritonitis induced by crystals and IL-1β. ^[3] The 2008 review anticipates that KPV may in the future be a suitable candidate for inflammatory skin and intestinal diseases, lung and eye inflammation, and arthritis; this is a projection, not a clinical finding. ^[2]

Has KPV been studied in humans?

According to the FDA, there are no data on the use of KPV in humans. According to the FDA’s assessment dated May 12, 2026, nominators of KPV submitted nine sources; none of them was a study in which KPV was used in humans, and the FDA’s own literature search also found no data such as a clinical study of KPV use in humans. Of the sources submitted, eight were animal studies with various α-MSH derivatives and one was an absorption study in human cadaver skin. ^[1]

The FDA also found no study examining the course of KPV in the human body (pharmacokinetics). According to the laboratory study with human cadaver skin, KPV does not pass well through the skin; the FDA writes that this may limit both systemic toxicity and possible efficacy in products applied to the skin. ^[1] The nominated uses were wound healing and inflammatory conditions such as psoriasis and eczema; the FDA concluded that there was no evidence to evaluate efficacy for these uses, and noted that approved treatments with proven efficacy exist for these diseases. ^[1]

What do oral, injectable and blend products promise?

According to the FDA’s internet survey, KPV is promoted alone in injectable, oral, topical and nasal spray forms, and also in blend products under the name “regenerative combination” together with substances such as BPC-157, TB-500, AOD-9604 and follistatin-344. ^[1] Uses put forward on websites include inflammatory bowel diseases, Crohn’s disease, mast cell activation syndrome, histamine intolerance, recovery after COVID-19, Lyme disease, mold toxicity, pain syndromes, psoriasis, wound healing, nerve damage and stroke protection, and reducing tumor growth. The FDA also notes that it is unclear for which of these claims a genuinely prepared product was used. ^[1]

Because the FDA found no human study or human exposure data for KPV, none of these claims has been tested in humans; there are also no human data for blends containing KPV. ^[1] The peptides named in blends are covered in separate guides: BPC-157, TB-500. The meaning of the “for research purposes” label: What does research peptide mean?

What are the risks and unknowns?

What is known about KPV’s safety amounts to a list of what is not known. According to the FDA’s assessment: ^[1]

• None of the studies of acute and repeat-dose toxicity, genetic damage (genotoxicity), reproductive and developmental toxicity, and cancer causation (carcinogenicity) was either submitted or found.
• Because there is no clinical study or exposure data in humans, possible safety risks are unknown.
• No KPV-related record was found in the FDA’s adverse event database (FAERS) through December 3, 2025, and no case report exists in the literature. The FDA stresses that the reporting system is voluntary and that pharmacies generally do not report adverse events; the absence of records does not mean safety.
• Peptides can generate an immune response (immunogenicity) and can aggregate; even two-amino-acid peptides have been shown to aggregate. The FDA writes that there are no data to conclude that KPV does not carry these risks.
• The bulk substance itself was considered “not well characterized”: its naming was not standard; information on impurities, aggregation and microbiological testing and a certificate of analysis were absent from the nomination file.

General peptide risks are in a separate guide: Peptide side effects

FDA, WADA and Türkiye: what is the legal status?

US: category 2, expert recommendation and committee vote

KPV had been nominated for use in drugs prepared in pharmacies (compounded) and placed in the category of substances that may present significant safety risks (category 2). On the FDA page dated April 22, 2026, it is in the table of substances withdrawn by nominators; in the same row, the FDA writes that it found no human exposure data on products containing KPV and that it lacks important safety information, including whether it would harm humans. ^[8]

In their assessment prepared for the July 23, 2026 advisory committee, FDA experts recommended that the free base and acetate forms of KPV not be added to the list of bulk substances pharmacies can use. The reasons: the substance is not well characterized physically and chemically, the extent of compounded use is unknown, and there is no information at all on safety and efficacy in humans. ^[1] According to a law firm summarizing the meeting, the committee (PCAC), contrary to the experts’ recommendation, recommended adding both forms to the list by a vote of 8 yes, 6 no, 1 abstention. The committee does not make law and does not grant approval; the FDA may accept, reject or hold the recommendation. Leaving category 2 also does not automatically give the substance category 1 status. ^[9] None of these processes is a drug approval.

Sport (WADA)

The WADA list valid from January 1, 2026 does not name KPV. Class S0 prohibits at all times (in and out of competition) pharmacological substances that are not covered in another section of the list and are not approved by any official health authority for therapeutic use in humans, and gives its examples with the phrase “including but not limited to”. ^[10] As relayed by the FDA, the European Medicines Agency does not list an approved product containing KPV. ^[1]

Türkiye

The TİTCK (Turkish Medicines and Medical Devices Agency) Licensed Human Medicinal Products List dated October 16, 2026 contains no product with KPV as an active substance. ^[11] Article 19 of Law No. 1262 punishes those who manufacture unlicensed preparations and those who knowingly sell, offer for sale or have sold them with imprisonment from one to five years; the same penalty is prescribed for those who sell, market or advertise a product that is not a preparation with the claim that it diagnoses or treats diseases. Importing preparations made abroad without a license for commercial purposes counts as smuggling. ^[12] Under Article 24 of Law No. 6197, medicines cannot be sold on the internet or in any other electronic medium. ^[13]

General legal framework of peptides: Are peptides legal?

Evidence table: claim, population and limits

Limits of this guide

This page summarizes published cell and animal studies and official agency assessments on KPV. It gives no dose, cycle, preparation, administration technique or product-sourcing information. Animal and cell findings are not evidence of benefit or safety in humans; intestinal complaints may be a sign of diseases that require diagnosis.